Skip to main content
Access Bio, Inc. logo

Access Bio, Inc. — Investor Relations & Filings

Ticker · 950130 ISIN · KR8840090003 LEI · 335800Q5TV77F4L9Q648 KO Manufacturing
Open in API
Filings indexed 247 across all filing types
Latest filing 2019-08-21 Interim / Quarterly Rep…
Country IN India
Listing KO 950130

About Access Bio, Inc.

https://accessbio.net/

Access Bio, Inc. is a company dedicated to the prevention and early diagnosis of infectious diseases through the research, development, and manufacturing of in vitro diagnostic solutions. Its portfolio includes rapid diagnostic tests (RDTs), immunochemical diagnostics, biosensors, and molecular diagnostic products. The company is recognized for commercializing high-quality tests to combat significant global health threats, including malaria, COVID-19, HIV, and HPV. With a large-scale manufacturing capacity, Access Bio distributes its products globally, serving as a key partner in global health, particularly in the fight against often-neglected diseases.

Recent filings

Filing Released Lang Actions
반기보고서 (2019.06)
Interim / Quarterly Report Classification · 1% confidence The document is a '반기보고서' (Semi-Annual Report) for the company '엑세스바이오' (Access Bio, Inc.) covering the period from 2019.01.01 to 2019.06.30. It contains detailed financial statements, management discussion and analysis, and corporate governance information, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2019
2019-08-21 Korean
임시주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is an official announcement of the results of an Extraordinary General Meeting (EGM) for Access Bio, dated 2019-08-21. It details the voting results for the appointment of directors and amendments to the articles of association. According to the filing definitions, official results from shareholder votes at any general meeting fall under the 'Declaration of Voting Results & Voting Rights Announcements' (DVA) category.
2019-08-21 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a regulatory filing required under the Capital Markets Act in South Korea when an entity's shareholding in a company (in this case, Access Bio) changes significantly. This document details the reporting entity (Wooridul Pharmaceutical), the number of shares held, the purpose of holding, and the history of changes. It is a standard regulatory disclosure form, not an announcement of a report, and fits the definition of a Major Shareholding Notification.
2019-08-21 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by a major shareholder (Choi Young-ho) and his special related parties in the company Access Bio. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema, as it tracks significant changes in ownership levels.
2019-08-08 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities. It details the shareholding changes of a specific individual (Choi Young Ho, CEO) in Access Bio, Inc. This type of filing is a standard regulatory disclosure for insider trading or changes in ownership by directors/executives, which corresponds to the 'Director's Dealing' category.
2019-08-08 Korean
최대주주변경
Director's Dealing Classification · 1% confidence The document is a formal regulatory filing regarding a change in the company's largest shareholder (maximum shareholder). It details the transition from the previous shareholder (Choi Young-ho) to the new shareholder (Woori-dul Pharmaceutical) due to stock collateral liquidation. This type of disclosure is a standard regulatory requirement for public companies to report changes in control or major shareholding structures. Since it does not fit into specific categories like 'Director's Dealing' (which is for individual insiders) or 'Major Shareholding Notification' (which is usually for external investors crossing thresholds), and it is a specific regulatory announcement of a corporate event, it is best classified as a Regulatory Filing (RNS).
2019-08-07 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.